[LCID Study Number: 20193006]
A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy
The purpose of this study is to find out if cabozantinib in combination with atezolizumab is effective in treating liver cancer compared to sorafenib alone in people who have not received prior treatment. This study will also examine how well people with liver cancer who have not received prior treatment tolerate cabozantinib alone, and how well it works in treating their cancer.
Primary Contact Email: [email protected]
Primary Contact Phone: 781-744-9553